Literature DB >> 9572265

Evidence for kappa- and mu-opioid receptor expression in C6 glioma cells.

L M Bohn1, M M Belcheva, C J Coscia.   

Abstract

The astrocytoma cell line rat C6 glioma has been used as a model system to study the mechanism of various opioid actions. Nevertheless, the type of opioid receptor(s) involved has not been established. Here we demonstrate the presence of high-affinity U69,593, endomorphin-1, morphine, and beta-endorphin binding in desipramine (DMI)-treated C6 cell membranes by performing homologous and heterologous binding assays with [3H]U69,593, [3H]morphine, or 125I-beta-endorphin. Naive C6 cell membranes displayed U69,593 but neither endomorphin-1, morphine, nor beta-endorphin binding. Cross-linking of 125I-beta-endorphin to C6 membranes gave labeled bands characteristic of opioid receptors. Moreover, RT-PCR analysis of opioid receptor expression in control and DMI-treated C6 cells indicate that both kappa- and mu-opioid receptors are expressed. There does not appear to be a significant difference in the level of mu nor kappa receptor expression in naive versus C6 cells treated with DMI over a 20-h period. Collectively, the data indicate that kappa- and mu-opioid receptors are present in C6 glioma cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9572265      PMCID: PMC2571951          DOI: 10.1046/j.1471-4159.1998.70051819.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  46 in total

1.  kappa-opioid receptor expression defines a phenotypically distinct subpopulation of astroglia: relationship to Ca2+ mobilization, development, and the antiproliferative effect of opioids.

Authors:  J A Gurwell; M J Duncan; K Maderspach; A Stiene-Martin; R P Elde; K F Hauser
Journal:  Brain Res       Date:  1996-10-21       Impact factor: 3.252

Review 2.  Microglia: a sensor for pathological events in the CNS.

Authors:  G W Kreutzberg
Journal:  Trends Neurosci       Date:  1996-08       Impact factor: 13.837

3.  Primary astroglial cultures derived from several rat brain regions differentially express mu, delta and kappa opioid receptor mRNA.

Authors:  B B Ruzicka; C A Fox; R C Thompson; F Meng; S J Watson; H Akil
Journal:  Brain Res Mol Brain Res       Date:  1995-12-28

4.  A potent and selective endogenous agonist for the mu-opiate receptor.

Authors:  J E Zadina; L Hackler; L J Ge; A J Kastin
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

5.  kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression.

Authors:  C C Chao; G Gekker; S Hu; W S Sheng; K B Shark; D F Bu; S Archer; J M Bidlack; P K Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

6.  Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gbetagamma.

Authors:  T Avidor-Reiss; I Nevo; R Levy; T Pfeuffer; Z Vogel
Journal:  J Biol Chem       Date:  1996-08-30       Impact factor: 5.157

7.  Buprenorphine differentially alters opioid receptor adaptation in rat brain regions.

Authors:  M M Belcheva; M T Ho; E G Ignatova; L B Jefcoat; J Barg; Z Vogel; R J McHale; F E Johnson; C J Coscia
Journal:  J Pharmacol Exp Ther       Date:  1996-06       Impact factor: 4.030

8.  Agonist-induced desensitization and down-regulation of delta opioid receptors alter the levels of their 125I-beta-endorphin cross-linked products in subcellular fractions from NG108-15 cells.

Authors:  M M Belcheva; E G Ignatova; E C Young; C J Coscia
Journal:  Biochemistry       Date:  1996-11-26       Impact factor: 3.162

9.  mu-Opioid receptor-induced Ca2+ mobilization and astroglial development: morphine inhibits DNA synthesis and stimulates cellular hypertrophy through a Ca(2+)-dependent mechanism.

Authors:  K F Hauser; A Stiene-Martin; M P Mattson; R P Elde; S E Ryan; C C Godleske
Journal:  Brain Res       Date:  1996-05-13       Impact factor: 3.252

10.  Occurrence of the opiate alkaloid-selective mu3 receptor in mammalian microglia, astrocytes and Kupffer cells.

Authors:  K Dobrenis; M H Makman; G B Stefano
Journal:  Brain Res       Date:  1995-07-24       Impact factor: 3.252

View more
  9 in total

1.  Mu-opioid agonist inhibition of kappa-opioid receptor-stimulated extracellular signal-regulated kinase phosphorylation is dynamin-dependent in C6 glioma cells.

Authors:  L M Bohn; M M Belcheva; C J Coscia
Journal:  J Neurochem       Date:  2000-02       Impact factor: 5.372

2.  Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade.

Authors:  L M Bohn; M M Belcheva; C J Coscia
Journal:  J Neurochem       Date:  2000-02       Impact factor: 5.372

3.  Evidence of endogenous mu opioid receptor regulation by epigenetic control of the promoters.

Authors:  Cheol Kyu Hwang; Kyu Young Song; Chun Sung Kim; Hack Sun Choi; Xiao-Hong Guo; Ping-Yee Law; Li-Na Wei; Horace H Loh
Journal:  Mol Cell Biol       Date:  2007-04-23       Impact factor: 4.272

4.  Morphine induces ubiquitin-proteasome activity and glutamate transporter degradation.

Authors:  Liling Yang; Shuxing Wang; Backil Sung; Grewo Lim; Jianren Mao
Journal:  J Biol Chem       Date:  2008-06-06       Impact factor: 5.157

5.  Morphine protects against methylmercury intoxication: a role for opioid receptors in oxidative stress?

Authors:  Allan Costa-Malaquias; Mauro B Almeida; José R Souza Monteiro; Barbarella de Matos Macchi; José Luiz M do Nascimento; María Elena Crespo-Lopez
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

6.  Efficacy of D,L-methadone in the treatment of glioblastoma in vitro.

Authors:  Konstantin Brawanski; Gero Brockhoff; Peter Hau; Arabel Vollmann-Zwerenz; Christian Freyschlag; Annette Lohmeier; Markus J Riemenschneider; Claudius Thomé; Alexander Brawanski; Martin A Proescholdt
Journal:  CNS Oncol       Date:  2018-06-19

7.  Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments.

Authors:  Jason Thomas Duskey; Arianna Rinaldi; Ilaria Ottonelli; Riccardo Caraffi; Chiara Alessia De Benedictis; Ann Katrin Sauer; Giovanni Tosi; Maria Angela Vandelli; Barbara Ruozi; Andreas Martin Grabrucker
Journal:  Pharmaceutics       Date:  2022-07-12       Impact factor: 6.525

8.  Therapeutic concentration of morphine reduces oxidative stress in glioma cell line.

Authors:  M B Almeida; A Costa-Malaquias; J L M Nascimento; K R Oliveira; A M Herculano; M E Crespo-López
Journal:  Braz J Med Biol Res       Date:  2014-05-02       Impact factor: 2.590

Review 9.  Opioids in cancer: The κ‑opioid receptor (Review).

Authors:  Qier Zhou; Zhiwei Zhang; Songkai Long; Wanjun Li; Baiyun Wang; Na Liang
Journal:  Mol Med Rep       Date:  2021-12-08       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.